These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32004727)

  • 1. Advancing serum peptidomic profiling by data-independent acquisition for clear-cell renal cell carcinoma detection and biomarker discovery.
    Lin L; Zheng J; Zheng F; Cai Z; Yu Q
    J Proteomics; 2020 Mar; 215():103671. PubMed ID: 32004727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis.
    Lin L; Zheng J; Yu Q; Chen W; Xing J; Chen C; Tian R
    J Proteomics; 2018 Mar; 174():9-16. PubMed ID: 29278786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma.
    Yang J; Yang J; Gao Y; Zhao L; Liu L; Qin Y; Wang X; Song T; Huang C
    PLoS One; 2014; 9(11):e111364. PubMed ID: 25368985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma.
    Ueda K; Saichi N; Takami S; Kang D; Toyama A; Daigo Y; Ishikawa N; Kohno N; Tamura K; Shuin T; Nakayama M; Sato TA; Nakamura Y; Nakagawa H
    PLoS One; 2011 Apr; 6(4):e18567. PubMed ID: 21533267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors.
    Gianazza E; Chinello C; Mainini V; Cazzaniga M; Squeo V; Albo G; Signorini S; Di Pierro SS; Ferrero S; Nicolardi S; van der Burgt YE; Deelder AM; Magni F
    J Proteomics; 2012 Dec; 76 Spec No.():125-40. PubMed ID: 22868251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma.
    Papale M; Vocino G; Lucarelli G; Rutigliano M; Gigante M; Rocchetti MT; Pesce F; Sanguedolce F; Bufo P; Battaglia M; Stallone G; Grandaliano G; Carrieri G; Gesualdo L; Ranieri E
    Oncotarget; 2017 Jun; 8(25):40412-40424. PubMed ID: 28418894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data-Independent Acquisition-Based Quantitative Proteomic Analysis Reveals Potential Biomarkers of Kidney Cancer.
    Song Y; Zhong L; Zhou J; Lu M; Xing T; Ma L; Shen J
    Proteomics Clin Appl; 2017 Dec; 11(11-12):. PubMed ID: 28975715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers.
    Padoan A; Basso D; Zambon CF; Prayer-Galetti T; Arrigoni G; Bozzato D; Moz S; Zattoni F; Bellocco R; Plebani M
    Clin Proteomics; 2018; 15():23. PubMed ID: 30065622
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
    DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data-Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform.
    Ritz D; Kinzi J; Neri D; Fugmann T
    Proteomics; 2017 Oct; 17(19):. PubMed ID: 28834231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing.
    Eikrem OS; Strauss P; Beisland C; Scherer A; Landolt L; Flatberg A; Leh S; Beisvag V; Skogstrand T; Hjelle K; Shresta A; Marti HP
    Scand J Urol; 2016 Dec; 50(6):452-462. PubMed ID: 27739342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
    Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
    J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor size, stage and grade alterations of urinary peptidome in RCC.
    Chinello C; Cazzaniga M; De Sio G; Smith AJ; Grasso A; Rocco B; Signorini S; Grasso M; Bosari S; Zoppis I; Mauri G; Magni F
    J Transl Med; 2015 Oct; 13():332. PubMed ID: 26482227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing Urinary Protein Biomarker Discovery by Data-Independent Acquisition on a Quadrupole-Orbitrap Mass Spectrometer.
    Muntel J; Xuan Y; Berger ST; Reiter L; Bachur R; Kentsis A; Steen H
    J Proteome Res; 2015 Nov; 14(11):4752-62. PubMed ID: 26423119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma.
    Zhang W; Ni M; Su Y; Wang H; Zhu S; Zhao A; Li G
    Eur Urol Focus; 2018 Apr; 4(3):412-419. PubMed ID: 28753793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
    Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
    Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Peptidome Comes of Age: Mass Spectrometry-Based Characterization of the Circulating Cancer Peptidome.
    Greening DW; Kapp EA; Simpson RJ
    Enzymes; 2017; 42():27-64. PubMed ID: 29054270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of data-independent acquisition workflows for metabolomic analysis on a quadrupole-orbitrap platform.
    Zhou J; Li Y; Chen X; Zhong L; Yin Y
    Talanta; 2017 Mar; 164():128-136. PubMed ID: 28107906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Strategy for Peptidomic LC-MS/MS Data Analysis: The Case of Urinary Peptidome Study.
    Zakharova NV; Bugrova AE; Indeykina MI; Brzhozovskiy AG; Nikolaev EN; Kononikhin AS
    Methods Mol Biol; 2024; 2758():389-399. PubMed ID: 38549026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.